Skip to content

April 27, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Commercial
Lilly falls on slower start for Foundayo versus Wegovy

Commercial

Lilly falls on slower start for Foundayo versus Wegovy

Pharmaphorum

Sky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.

Metabolic & GLP-1

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

Pharmaphorum

Sky-high expectations for sales of Eli Lilly’s new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.

Metabolic & GLP-1

Read full story

Post navigation

Previous: UK biotech could be bound for recovery, BIA report reveals

Next: New NIHR-funded TRC for Parkinson’s disease

Related Stories

Commercial

Daiichi Sankyo shares slip after delaying annual earnings report

pharminent April 24, 2026

Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

pharminent April 24, 2026

Commercial

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

pharminent April 23, 2026

You May Have Missed

Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

pharminent April 27, 2026

Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.